In agreement, Guasch et al. [39] observed that the oral administration of MK-591, a FLAP antagonist, restored the glomerular size selectivity without any changes in GFR in patients with glomerulonephritis, resulting in lower levels of proteinuria. This evidence concerns the gene ALOX5AP and glomerulonephritis.